{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T12:39:45Z","timestamp":1785155985738,"version":"3.55.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100020549","name":"Centre L\u00e9on B\u00e9rard","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020549","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.esmoop.2026.106946","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T16:49:46Z","timestamp":1775753386000},"page":"106946","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Durvalumab combined with weekly carboplatin\/paclitaxel as first-line treatment of patients with recurrent and\/or metastatic HNSCC not eligible for cisplatin-based chemotherapies: results of the multicenter prospective study FRAIL-IMMUNE"],"prefix":"10.1016","volume":"11","author":[{"given":"J.","family":"Fayette","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Cropet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Toullec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Burgy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Bruyas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Sire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Lagrange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Clatot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Vinches","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Iacob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.-C.","family":"Kaminsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Vansteene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Salas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Champagnac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8090-9323","authenticated-orcid":false,"given":"P.","family":"Saintigny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Gautier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"P\u00e9rol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Bourhis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10212","key":"10.1016\/j.esmoop.2026.106946_bib1","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.esmoop.2026.106946_bib2","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1200\/JCO.21.02198","article-title":"Pembrolizumab alone or with chemotherapy for recurrent\/metastatic head and neck squamous cell carcinoma in KEYNOTE-048: subgroup analysis by programmed death ligand-1 combined positive score","volume":"40","author":"Burtness","year":"2022","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2026.106946_bib4","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1200\/JCO.21.02508","article-title":"Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: updated results of the phase III KEYNOTE-048 study","volume":"41","author":"Harrington","year":"2023","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2026.106946_bib5","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S1470-2045(20)30755-5","volume":"22","author":"Guigay","year":"2021","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2026.106946_bib6","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1200\/JCO.22.01408","article-title":"Immunotherapy, chemotherapy, or both: options for first-line therapy for patients with recurrent or metastatic head and neck squamous cell carcinoma","volume":"41","author":"Ho","year":"2023","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2026.106946_bib7","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1200\/JCO.1992.10.8.1245","article-title":"Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study","volume":"10","author":"Forastiere","year":"1992","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106946_bib8","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/COC.0b013e3182019ee3","article-title":"Weekly paclitaxel and carboplatin induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck","volume":"35","author":"Ready","year":"2012","journal-title":"Am J Clin Oncol"},{"issue":"18","key":"10.1016\/j.esmoop.2026.106946_bib9","doi-asserted-by":"crossref","first-page":"4509","DOI":"10.3390\/cancers14184509","article-title":"Targeting the tumor microenvironment through mTOR inhibition and chemotherapy as induction therapy for locally advanced head and neck squamous cell carcinoma: the CAPRA study","volume":"14","author":"Evrard","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"31","key":"10.1016\/j.esmoop.2026.106946_bib10","doi-asserted-by":"crossref","first-page":"22038","DOI":"10.18632\/oncotarget.25157","article-title":"Carboplatin in combination with weekly Paclitaxel as first-line therapy in patients with recurrent\/metastatic head and neck squamous cell carcinoma unfit to EXTREME schedule","volume":"9","author":"P\u00eatre","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.esmoop.2026.106946_bib11","series-title":"Critical Issues in Head and Neck Oncology [Internet]","first-page":"267","article-title":"Are there alternative chemotherapy regimens for EXTREME in recurrent\/metastatic squamous cell carcinoma of the head and neck (R\/M-SCCHN)?","author":"Guigay","year":"2018"},{"issue":"11","key":"10.1016\/j.esmoop.2026.106946_bib12","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","article-title":"Platinum-based chemotherapy plus cetuximab in head and neck cancer","volume":"359","author":"Vermorken","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.esmoop.2026.106946_bib13","doi-asserted-by":"crossref","first-page":"668","DOI":"10.3389\/fonc.2019.00668","article-title":"The evolving role of taxanes in combination with cetuximab for the treatment of recurrent and\/or metastatic squamous cell carcinoma of the head and neck: evidence, advantages, and future directions","volume":"9","author":"Guigay","year":"2019","journal-title":"Front Oncol"},{"issue":"25","key":"10.1016\/j.esmoop.2026.106946_bib14","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1200\/JCO.23.02625","article-title":"Pembrolizumab plus carboplatin and paclitaxel as first-line therapy for recurrent\/metastatic head and neck squamous cell carcinoma (KEYNOTE-B10): a single-arm phase IV trial","volume":"42","author":"Dzienis","year":"2024","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2026.106946_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers12113110","volume":"12","author":"Tsakonas","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"12","key":"10.1016\/j.esmoop.2026.106946_bib16","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.21.01308","article-title":"Five-year survival outcomes from the PACIFIC Trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J Clin Oncol"},{"issue":"10212","key":"10.1016\/j.esmoop.2026.106946_bib17","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum\u2013etoposide versus platinum\u2013etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.esmoop.2026.106946_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid"},{"issue":"3","key":"10.1016\/j.esmoop.2026.106946_bib19","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1200\/JCO.23.02132","article-title":"Durvalumab plus carboplatin\/paclitaxel followed by maintenance durvalumab with or without olaparib as first-line treatment for advanced endometrial cancer: the phase III DUO-E trial","volume":"42","author":"Westin","year":"2024","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2026.106946_bib20","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1097\/HEP.0000000000001385","article-title":"Immune-mediated adverse events and overall survival with tremelimumab plus durvalumab and durvalumab monotherapy in unresectable hepatocellular carcinoma: HIMALAYA Phase 3 randomized clinical trial","volume":"83","author":"Lau","year":"2026","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.esmoop.2026.106946_bib21","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.annonc.2022.12.008","article-title":"Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study","volume":"34","author":"Psyrri","year":"2023","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2026.106946_bib22","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.annonc.2020.04.001","article-title":"Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study","volume":"31","author":"Ferris","year":"2020","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2026.106946_bib23","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2026.106946_bib25","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ejca.2017.06.027","article-title":"Prognostic value of the G8 and modified-G8 screening tools for multidimensional health problems in older patients with cancer","volume":"83","author":"Martinez-Tapia","year":"2017","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.esmoop.2026.106946_bib26","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"JNCI J Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.esmoop.2026.106946_bib27","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1200\/JCO.1999.17.3.1008","article-title":"Quality of life in head and neck cancer patients: validation of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-H& N35","volume":"17","author":"Bjordal","year":"1999","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.esmoop.2026.106946_bib28","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1200\/JCO.2016.70.1524","article-title":"Pembrolizumab for platinum- and cetuximab-refractory head and neck cancer: results from a single-arm, phase II study","volume":"35","author":"Bauml","year":"2017","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2026.106946_bib29","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1200\/JCO.22.00332","article-title":"Nivolumab plus ipilimumab versus EXTREME regimen as first-line treatment for recurrent\/metastatic squamous cell carcinoma of the head and neck: the final results of CheckMate 651","volume":"41","author":"Haddad","year":"2023","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2026.106946_bib30","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.18632\/aging.203919","article-title":"Comparison of one-week versus three-week paclitaxel for advanced pan-carcinomas: systematic review and meta-analysis","volume":"14","author":"Lin","year":"2022","journal-title":"Aging (Albany NY)"},{"issue":"5","key":"10.1016\/j.esmoop.2026.106946_bib31","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1016\/j.ijrobp.2024.01.016","article-title":"Pembrolizumab with or without lenvatinib as first-line therapy for recurrent or metastatic head and neck squamous cell carcinoma (R\/M HNSCC): phase 3 LEAP-010 study","volume":"118","author":"Licitra","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.esmoop.2026.106946_bib32","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/CCO.0000000000000834","article-title":"Systemic treatment of recurrent and\/or metastatic squamous cell carcinomas of the head and neck: what is the best therapeutic sequence?","volume":"34","author":"Saada-Bouzid","year":"2022","journal-title":"Curr Opin Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2026.106946_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3892\/mco.2021.2403","article-title":"Weekly vs. 3-weekly paclitaxel, carboplatin, and cetuximab (PCC) in recurrent\/metastatic head and neck cancer","volume":"15","author":"Geraghty","year":"2021","journal-title":"Mol Clin Oncol"},{"issue":"suppl 16","key":"10.1016\/j.esmoop.2026.106946_bib34","article-title":"Weekly paclitaxel (P), carboplatin (CP) plus pembrolizumab (PMB) as first-line treatment of recurrent or metastatic (R\/M) or locally very advanced (LVA) head and neck squamous cell carcinoma (HNSCC): a retrospective study in 39 patients (pts)","volume":"42","author":"Borel","year":"2023","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2026.106946_bib35","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1007\/s12325-025-03144-4","article-title":"Pembrolizumab with carboplatin and paclitaxel versus alternative systemic treatments recommended for the first-line treatment of recurrent\/metastatic head and neck cancer: an indirect treatment comparison","volume":"42","author":"Dzienis","year":"2025","journal-title":"Adv Ther"},{"issue":"suppl 15","key":"10.1016\/j.esmoop.2026.106946_bib36","article-title":"Landmark analysis of immunotherapy duration and disease free survival in advanced melanoma patients with a complete response","volume":"15","author":"Selig","year":"2020","journal-title":"J Clin Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926008884?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926008884?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T15:31:23Z","timestamp":1776699083000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702926008884"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S2059702926008884"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.106946","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Durvalumab combined with weekly carboplatin\/paclitaxel as first-line treatment of patients with recurrent and\/or metastatic HNSCC not eligible for cisplatin-based chemotherapies: results of the multicenter prospective study FRAIL-IMMUNE","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.106946","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"106946"}}